Mednax, Inc (NYSE:MD) insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the sale, the insider now directly owns 35,569 shares in the company, valued at $1,834,649.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Mednax, Inc (NYSE MD) traded up $0.25 during midday trading on Wednesday, reaching $51.68. 782,200 shares of the company traded hands, compared to its average volume of 1,093,204. Mednax, Inc has a fifty-two week low of $40.56 and a fifty-two week high of $72.13. The firm has a market capitalization of $4,816.69, a price-to-earnings ratio of 15.73, a P/E/G ratio of 1.66 and a beta of 0.40. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37.

Mednax (NYSE:MD) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.87. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The business had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. During the same period in the prior year, the business posted $1.09 earnings per share. Mednax’s revenue was up 4.9% compared to the same quarter last year. equities research analysts anticipate that Mednax, Inc will post 3.1 earnings per share for the current fiscal year.

A number of equities analysts have recently issued reports on the stock. Piper Jaffray Companies assumed coverage on shares of Mednax in a research report on Wednesday. They set an “overweight” rating and a $58.00 target price on the stock. Jefferies Group reiterated a “hold” rating and set a $46.00 target price on shares of Mednax in a research report on Tuesday, October 3rd. Robert W. Baird reiterated a “hold” rating and set a $47.00 target price on shares of Mednax in a research report on Sunday, September 3rd. KeyCorp set a $51.00 target price on shares of Mednax and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, Citigroup reduced their target price on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, November 3rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $53.70.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its holdings in Mednax by 0.3% in the second quarter. BlackRock Inc. now owns 8,257,495 shares of the company’s stock valued at $498,505,000 after buying an additional 28,155 shares during the period. Vanguard Group Inc. lifted its holdings in Mednax by 0.5% in the second quarter. Vanguard Group Inc. now owns 7,551,130 shares of the company’s stock valued at $455,862,000 after buying an additional 38,645 shares during the period. Thompson Siegel & Walmsley LLC lifted its holdings in Mednax by 19.7% in the third quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock valued at $112,065,000 after buying an additional 428,184 shares during the period. Victory Capital Management Inc. lifted its holdings in Mednax by 22.6% in the second quarter. Victory Capital Management Inc. now owns 2,423,865 shares of the company’s stock valued at $146,329,000 after buying an additional 446,074 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in Mednax by 4.8% in the third quarter. Nordea Investment Management AB now owns 2,323,695 shares of the company’s stock valued at $100,198,000 after buying an additional 106,883 shares during the period. Institutional investors and hedge funds own 98.48% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Mednax, Inc (MD) Insider John C. Pepia Sells 3,000 Shares” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/12/13/mednax-inc-md-insider-john-c-pepia-sells-3000-shares.html.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Insider Buying and Selling by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with MarketBeat.com's FREE daily email newsletter.